carbamazepine has been researched along with Brain Damage, Chronic in 12 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following pilocarpine-induced status epilepticus interrupted after 4h, rats were continuously videorecorded for onset and recurrence of spontaneous convulsive seizures." | 7.73 | Drug resistance and hippocampal damage after delayed treatment of pilocarpine-induced epilepsy in the rat. ( Bentivoglio, M; Chakir, A; Fabene, PF; Ouazzani, R, 2006) |
| " Following pilocarpine-induced status epilepticus interrupted after 4h, rats were continuously videorecorded for onset and recurrence of spontaneous convulsive seizures." | 3.73 | Drug resistance and hippocampal damage after delayed treatment of pilocarpine-induced epilepsy in the rat. ( Bentivoglio, M; Chakir, A; Fabene, PF; Ouazzani, R, 2006) |
| " Here we determined whether chronic administration of common AEDs during early life alters cell proliferation and neurogenesis in the hippocampus." | 1.35 | Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. ( Cai, F; Cao, J; Chen, J; Li, S; Zhang, X, 2009) |
| "Treatment with carbamazepine, verapamil, and fluoxetine greatly improved the patient's symptoms." | 1.29 | Neurobehavioural dysfunction following mild traumatic brain injury in childhood: a case report with positive findings on positron emission tomography (PET). ( Bushnell, DL; Hines, ME; Manshadi, FF; Roberts, MA, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (75.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Cai, F | 1 |
| Cao, J | 1 |
| Zhang, X | 1 |
| Li, S | 1 |
| Horvath, J | 1 |
| Coeytaux, A | 1 |
| Jallon, P | 1 |
| Landis, T | 1 |
| Temperli, P | 1 |
| Burkhard, PR | 1 |
| Chakir, A | 1 |
| Fabene, PF | 1 |
| Ouazzani, R | 1 |
| Bentivoglio, M | 1 |
| Roberts, MA | 1 |
| Manshadi, FF | 1 |
| Bushnell, DL | 1 |
| Hines, ME | 1 |
| Rivey, MP | 1 |
| Allington, DR | 1 |
| Stone, JD | 1 |
| Serfoss, ML | 1 |
| Jawad, S | 1 |
| Clarke, E | 1 |
| Richens, A | 1 |
| Helmstaedter, C | 1 |
| Wagner, G | 1 |
| Elger, CE | 1 |
| Sechi, G | 1 |
| Casu, AR | 1 |
| Rosati, G | 1 |
| Spanu, A | 1 |
| Deserra, F | 1 |
| Nuvoli, S | 1 |
| Deiana, GA | 1 |
| Madeddu, G | 1 |
| Cocito, L | 1 |
| Primavera, A | 1 |
| Sugarman, P | 1 |
| Lewin, J | 1 |
| Sumners, D | 1 |
| McNamara, ME | 1 |
| Fogel, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial[NCT00621751] | 70 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 2.9 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.3 |
| Placebo | 3.1 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: Day-42
| Intervention | score on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 3.1 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome was a composite measure of observer-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., observer-rated NPI-I/A Rasch construct scores). Mean day-42 observer-rated NPI-I/A Rasch construct scores were compared between placebo vs. carbamazepine using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: 42 days
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.7 |
| Placebo | 36.7 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, a composite measure of participant-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., participant-rated NPI-I/A Rasch construct scores). Mean day-42 participant-rated NPI-I/A Rasch construct scores were compared between placebo vs. CBZ using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: Day 42
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.5 |
| Placebo | 36.4 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Observer. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: 42-day
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 20 |
| Placebo | 26 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Participant. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: Day-42
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 21 |
| Placebo | 16 |
1 trial available for carbamazepine and Brain Damage, Chronic
| Article | Year |
|---|---|
Cerebral and cerebellar diaschisis following carbamazepine therapy.
Topics: Adolescent; Adult; Blood Flow Velocity; Brain Damage, Chronic; Carbamazepine; Cerebrovascular Circul | 1995 |
11 other studies available for carbamazepine and Brain Damage, Chronic
| Article | Year |
|---|---|
Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain.
Topics: Age Factors; Animals; Animals, Suckling; Anticonvulsants; Apoptosis; Brain Damage, Chronic; Carbamaz | 2009 |
Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Atrophy; Basal Ganglia; Brain; Brain Damage, Chronic; Carbam | 2005 |
Drug resistance and hippocampal damage after delayed treatment of pilocarpine-induced epilepsy in the rat.
Topics: Animals; Anticonvulsants; Brain Damage, Chronic; Carbamazepine; Convulsants; Disease Models, Animal; | 2006 |
Neurobehavioural dysfunction following mild traumatic brain injury in childhood: a case report with positive findings on positron emission tomography (PET).
Topics: Accidents, Traffic; Anticonvulsants; Antidepressive Agents, Second-Generation; Brain Concussion; Bra | 1995 |
Alteration of carbamazepine pharmacokinetics in patients with traumatic brain injury.
Topics: Adult; Brain Damage, Chronic; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Ep | 1995 |
Vigabatrin-induced psychosis--management problems.
Topics: Adult; Brain Damage, Chronic; Carbamazepine; Female; gamma-Aminobutyric Acid; Humans; Psychoses, Sub | 1994 |
Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy.
Topics: Attention; Brain Damage, Chronic; Carbamazepine; Cognition Disorders; Electroencephalography; Epilep | 1993 |
Vigabatrin aggravates absences and absence status.
Topics: Adult; Anticonvulsants; Asphyxia; Brain Damage, Chronic; Carbamazepine; Drug Therapy, Combination; E | 1998 |
Carbamazepine and episodic dyscontrol.
Topics: Adult; Aggression; Brain Damage, Chronic; Carbamazepine; Epilepsy; Humans; Male; Violence | 1992 |
Successful treatment of episodic dyscontrol with carbamazepine.
Topics: Adolescent; Aggression; Brain Damage, Chronic; Carbamazepine; Dose-Response Relationship, Drug; Head | 1992 |
Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities.
Topics: Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Carbamazepine; Clonazepam; Electroencepha | 1990 |